ImmunityBio (IBRX): Assessing Valuation After Revealing Landmark ANKTIVA Results in Advanced Lung Cancer Study
ImmunityBio (IBRX) has announced landmark results for its drug ANKTIVA in advanced non-small cell lung cancer, showing sustained survival benefits and reversal of lymphopenia. This positive clinical trial data, combined with promising signs in other indications like glioblastoma, suggests a significant shift for the company, whose stock price has struggled recently. Despite trading at a high price-to-sales ratio, the company is deemed undervalued by a discounted cash flow model, reflecting investor optimism about its drug pipeline.
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch
ImmunityBio has partnered with Accord Healthcare to expand access to its immunotherapy ANKTIVA® in the European Union, UK, and EFTA members. This collaboration includes an 85-person sales force and the establishment of an Irish subsidiary to support distribution. ANKTIVA is indicated for BCG-unresponsive non-muscle invasive bladder cancer and has now received regulatory authorization in 33 countries, aiming to meet the needs of approximately 157,000 people diagnosed annually in the EU and UK.
ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average
ImmunityBio Inc (NASDAQ: IBRX) is exhibiting a strong long-term uptrend, marked by a confirmed Golden Cross and trading roughly 170% above its 200-day moving average. The stock is also positioned above its 20-day and 50-day moving averages, reinforcing its sustained price strength across various timeframes. Elevated momentum indicators, including an RSI of 67, further support the positive outlook, suggesting continued buying pressure.
ImmunityBio Wins EU Nod for ANKTIVA Bladder Cancer Therapy
ImmunityBio (IBRX) received conditional marketing authorization from the European Commission for ANKTIVA in combination with BCG to treat non-muscle invasive bladder cancer. This authorization makes ANKTIVA the first authorized immunotherapy for this high-risk bladder cancer population in 33 European countries. The approval aligns with strong technical sentiment for IBRX, despite financial health concerns, and expands the company's global oncology footprint.
ImmunityBio gets EC conditional approval for ANKTIVA with BCG, expanding authorization to 33 countries
ImmunityBio received conditional marketing authorization from the European Commission for ANKTIVA with BCG to treat BCG-unresponsive NMIBC CIS. This approval expands the drug's availability to 33 countries, including all 27 EU member states plus Iceland, Norway, and Liechtenstein. The decision was based on data from the QUILT-3.032 trial, which showed a 71% complete response rate and a median duration of response of 26.6 months.
How High Can IBRX Stock Go Now? Here’s What Wall Street Thinks After Saudi Nod For Bladder Cancer Filing
ImmunityBio (IBRX) stock saw a bump after Saudi regulators encouraged a filing for their bladder cancer therapy and initiated discussions for expanding Anktiva to other tumor types. Analysts, including D. Boral Capital, project a significant upside with a $24 price target, implying nearly 300% growth. The company is also pushing back against stricter FDA standards in the U.S. for Anktiva's broader application.
ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia
ImmunityBio engaged in productive regulatory discussions with the Saudi Food and Drug Authority (SFDA) during the USA-Saudi Biotech Alliance Meeting. The SFDA encouraged ImmunityBio to submit a regulatory package for its recombinant BCG (rBCG) to address the global BCG shortage and also initiated discussions for expanding the use of ANKTIVA® in combination with checkpoint inhibitors for additional tumor types. This engagement builds on ImmunityBio's existing approvals in Saudi Arabia and signifies a deepening relationship aiming to advance access to innovative immunotherapies and address crucial medical needs in the region.
IBRX Stock Jumps 6% Pre-Market On BCG Update In Saudi Arabia – Retail Says Share Price Is ‘Attractive’
ImmunityBio's stock (IBRX) rose 6% pre-market after the Saudi Food and Drug Authority encouraged a regulatory filing for its recombinant Bacillus Calmette-Guérin (rBCG) to address local shortages and expand cancer treatment access. The company also initiated discussions to broaden the use of its therapy ANKTIVA for multiple tumor types. Despite overall bearish sentiment from retail traders on Stocktwits, some users view the share price as attractive, contributing to a 210% year-to-date gain.
ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia
ImmunityBio held productive regulatory discussions with the Saudi Food and Drug Authority (SFDA) regarding the submission of a regulatory package for its recombinant BCG (rBCG) to address the global BCG shortage in Saudi Arabia. The discussions also covered the expansion of ANKTIVA in combination with checkpoint inhibitors for additional tumor types, building on its accelerated approval for metastatic non-small cell lung cancer. ImmunityBio plans to submit the rBCG package soon and establish a regional office in Saudi Arabia, which is becoming a critical market for the company's portfolio.
D. Boral Capital Reiterates "Buy" Rating for ImmunityBio (NASDAQ:IBRX)
D. Boral Capital has reiterated its "Buy" rating for ImmunityBio (NASDAQ:IBRX) with a price target of $24.00, suggesting a significant upside of 303% from its current price. While the broader analyst consensus is a "Moderate Buy" with an average target of $11.80, D. Boral's projection stands out. ImmunityBio, a clinical-stage biotechnology company focused on immunotherapies for cancer and infectious diseases, has recently seen insider selling but maintains high insider and institutional ownership.
Saudi FDA encourages ImmunityBio to submit rBCG regulatory file
ImmunityBio, Inc. engaged in regulatory discussions with the Saudi Food and Drug Authority (SFDA), which urged the biotech firm to submit a regulatory package for its recombinant BCG (rBCG) to address a shortage impacting bladder cancer patients. The SFDA also initiated discussions for expanding ANKTIVA (nogapendekin alfa inbakicept) for various tumor types. Despite a recent stock drop, ImmunityBio has seen significant year-to-date gains and has several ongoing clinical and regulatory developments.
ImmunityBio Reports Productive Regulatory Engagement with Saudi Food and Drug Authority at USA-Saudi Biotech Alliance Meeting Hosted by the Ministry of Investment of Saudi Arabia
ImmunityBio held productive regulatory discussions with the Saudi Food and Drug Authority (SFDA) regarding two key areas: the submission of a regulatory package for its recombinant BCG (rBCG) to address a global shortage and the expansion of its ANKTIVA® (nogapendekin alfa inbakicept) combination therapy to additional tumor types. The SFDA encouraged the rBCG submission and has already approved ANKTIVA for two indications in Saudi Arabia, building on the Saudi-USA Biotech Alliance's framework. The company plans to establish a regional office and a wholly-owned subsidiary in Saudi Arabia to support its Middle East and North Africa strategy.
Why ImmunityBio (IBRX) stock is up 7% in premarket — and what traders are watching next
ImmunityBio (IBRX) shares rose 7% in premarket trading after a significant drop on Friday, with investors watching for updates on its cancer therapy, Anktiva. The stock's performance is currently amplified by thin premarket liquidity following a holiday. Traders are looking toward upcoming oncology meetings and quarterly updates for cues on the company's future trajectory.
Roger Stone Interviews Dr. Patrick Soon-Shiong
The article announces an interview between Roger Stone and Dr. Patrick Soon-Shiong, the founder of ImmunityBio. It highlights ImmunityBio's focus on developing targeted, personalized immunotherapies to combat disease by enhancing the immune system. The company is actively pursuing new treatments and clinical trials, offering solutions for patients, trial investigators, and research scientists.
Exploring New Approaches in Glioblastoma Treatment – ImmunityBio
ImmunityBio recently highlighted its ongoing commitment to glioblastoma research via a post on X. The company acknowledged the significant scientific and clinical hurdles posed by glioblastoma and the urgent need for better treatment options. ImmunityBio's efforts are concentrated on advancing studies to deepen the understanding of this cancer and develop innovative therapeutic approaches.
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ
This NASDAQ page provides live quotes and charts for ImmunityBio Inc. (IBRX), showing its current stock price and recent performance. It notes that the company's earnings information is not currently available and that there are no analyst ratings within the last three months. The page also features an invitation to join options trading sessions and free trade alerts.
ImmunityBio Sees Unusually High Options Volume (NASDAQ:IBRX)
ImmunityBio (NASDAQ:IBRX) experienced unusually high options trading volume on Friday, with investors purchasing 25,953 call options, a 46% increase over the daily average. This comes amidst recent insider selling by directors Barry J. Simon and Christobel Selecky, though insiders still own a significant 69.48% of the company. Analysts hold a "Moderate Buy" consensus rating with an average target price of $11.80, considerably higher than the stock's recent trading price of $6.49.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
Pomerantz LLP is investigating ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of investors for potential securities fraud or unlawful business practices. This investigation follows a 12.13% stock price drop on January 23, 2026, after ImmunityBio announced Phase 2 clinical results for a glioblastoma immunotherapy, indicating that median overall survival had not yet been reached. Investors affected by these developments are encouraged to contact the law firm.
ImmunityBio Advances Chemotherapy Free Immunotherapies And Faces Key Investor Tests
ImmunityBio is making significant strides in chemotherapy-free immunotherapies, participating in the 2026 ASCO Genitourinary Cancers Symposium and expanding the use of its Anktiva therapy for lung cancer in Saudi Arabia. The company has also launched a Phase 2 trial for a chemotherapy-free regimen for non-Hodgkin lymphoma. While addressing financial challenges and share price volatility, these developments position ImmunityBio for potential growth in the immuno-oncology market.
ImmunityBio Stock Has Jumped 230% in a Year: How Anktiva’s 431% Sales Surge Is Driving IBRX
ImmunityBio (IBRX) stock has seen a 230% increase over the past year, driven by the significant sales growth of its drug Anktiva, which saw a 431% year-over-year revenue surge in Q4 2025. The company has also received positive regulatory approvals for Anktiva in multiple regions and is advancing discussions with the U.S. FDA for further indications. Despite strong top-line growth and high gross margins, ImmunityBio remains unprofitable, with significant R&D investments and cash burn, leading to continued stock volatility.
ImmunityBio (IBRX) Jumps Ahead of Oncology Event
ImmunityBio (IBRX) saw its share prices jump by 14.55% as investors anticipated its participation in the 2026 ASCO Genitourinary Cancers Symposium. The company is also expanding its cancer treatment, Anktiva, into Saudi Arabia for lung cancer patients after securing FDA approval there, expecting a significant sales jump.
ImmunityBio's Immunotherapy ANKTIVA Sparks Revenue Surge as Global Expansion Accelerates (IBRX, NNVC)
ImmunityBio reported a 700% year-over-year increase in preliminary net product revenue for 2025, reaching approximately $113 million, driven by its immunotherapy ANKTIVA. The company is expanding ANKTIVA's reach globally with approvals in the Middle East and a positive opinion in the EU, while also advancing its clinical pipeline for "chemo-free" treatments. Separately, NanoViricides announced progress in its antiviral drug NV-387, which has completed Phase I trials and is ready for Phase II testing against Mpox.
ImmunityBio stock steadies near $7 after 15% jump; earnings next up
ImmunityBio (NASDAQ: IBRX) shares stabilized near $7 after a 14.6% surge, with investors now focusing on the company's financial performance as a commercial-stage entity. The company's preliminary 2025 net product revenue for its cancer immunotherapy, Anktiva, was $113 million, a 700% year-over-year increase. Analysts expect upcoming earnings in early March to provide further clarity on the company's growth trajectory and its competition in the NMIBC treatment space.
ImmunityBio’s Stock Soars on Promising Trial Results and Strategic Advances
ImmunityBio Inc. (NASDAQ: IBRX) saw its stock surge by 8.35% due to promising clinical trial results for non-small cell lung cancer, bladder cancer, and Waldenstrom Lymphoma, alongside key regulatory approvals. The company reported a significant 700% year-over-year sales increase, reaching $113M, and secured accelerated FDA approval in Saudi Arabia for ANKTIVA, bolstering its global expansion strategy. Investors are closely watching its strategic advancements and financial performance as it continues to penetrate new markets and deliver positive clinical outcomes.
New Sign-Off Propels ImmunityBio
ImmunityBio Inc. shares surged following Saudi Arabia's approval of its Anktiva drug for bladder cancer, with further gains after a successful meeting with the FDA regarding a resubmission for another bladder cancer indication. The company plans to open a regional office in Saudi Arabia and expects final EU approval for Anktiva later this year. These developments led to a significant increase in ImmunityBio's stock value, despite some profit-taking.
Did ImmunityBio’s (IBRX) New Chemotherapy‑Free CAR‑NK Phase 2 Trial Just Redefine Its Investment Narrative?
ImmunityBio (IBRX) has launched the ResQ215B Phase 2 outpatient trial, which tests a chemotherapy-free combination for indolent B-cell non-Hodgkin lymphoma. This trial reinforces the company's IL-15 platform and off-the-shelf cell therapies as a broad platform rather than a single-asset approach. While this adds potential value, the company still faces risks related to cash runway, regulatory decisions in bladder cancer, and potential dilution.
Soon-Shiong Defends ImmunityBio Financing Pact for Cancer Drug
Dr. Patrick Soon-Shiong is defending a financing arrangement with ImmunityBio Inc. in a Delaware court, arguing it was crucial for the regulatory approval of their bladder cancer drug, Anktiva. This defense comes amidst a lawsuit from an investor who alleges Soon-Shiong misled investors and received a significant personal financial gain from the transactions preceding the drug's approval.
ImmunityBio Shares Maintain Upward Momentum on Clinical and Commercial Progress
ImmunityBio is experiencing significant growth in early 2026 due to clinical and commercial advancements. The company initiated a Phase 2 trial for a chemotherapy-free lymphoma treatment and reported preliminary annual revenue of $113 million for its ANKTIVA product, a nearly 700% increase year-over-year. Regulatory approval for ANKTIVA in Saudi Arabia and a pending FDA label expansion for bladder cancer treatment further underscore the company's progress, with its stock up over 200% year-to-date.
Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs
Immunitybio (IBRX) has launched a mid-stage clinical study for an off-the-shelf cell therapy to treat indolent non-Hodgkin lymphoma without the need for chemotherapy. This new trial builds on previous data showing durable responses and aims to enhance anti-tumor activity by combining the CD19 CAR-NK cell therapy with Anktiva and Rituximab. The company is also working to resubmit an application for Anktiva for bladder cancer treatment after a previous rejection.
ImmunityBio launches phase 2 trial for chemotherapy-free lymphoma therapy
ImmunityBio, Inc. (NASDAQ:IBRX) has commenced a Phase 2 clinical trial for a new chemotherapy-free immunotherapy combination targeting indolent B-cell non-Hodgkin lymphoma. The trial, ResQ215B, will evaluate the company's CD19-targeted natural killer cell therapy alongside ANKTIVA and rituximab, aiming to offer an alternative to traditional CAR-T therapies that require lymphodepleting chemotherapy. Despite the company not yet being profitable, its shares have seen a significant surge, and analysts anticipate continued sales growth.
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
ImmunityBio has initiated a Phase 2 clinical trial (ResQ215B) for a chemotherapy-free CAR-NK cell therapy combination (CD19 t-haNK, ANKTIVA®, and rituximab) to treat indolent non-Hodgkin lymphoma, including Waldenström’s Macroglobulinemia. This trial builds on previous Phase 1 results showing durable complete responses without chemotherapy and aims to further enhance immune-mediated anti-tumor activity through the addition of ANKTIVA. The regimen is designed to be an outpatient treatment, potentially transforming the treatment paradigm for these lymphomas by avoiding toxicities associated with traditional therapies.
Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)'s ANKTIVA Following QUILT Data
Piper Sandler has raised its price target for ImmunityBio, Inc. (IBRX) to $7 from $5 and maintained an Overweight rating, citing significant year-over-year growth in ANKTIVA net sales and anticipated label expansion potential in 2027 based on positive QUILT-2.005 data expected in Q4 2026. The company also reported promising Phase 2 QUILT-3.078 results for recurrent GBM, showing extended survival rates and a favorable safety profile. ImmunityBio specializes in developing immunotherapies and vaccines to combat cancers and infectious diseases.
Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data
Piper Sandler has identified label expansion potential for ImmunityBio, Inc.'s ANKTIVA, raising its price target to $7 and maintaining an Overweight rating. This optimism stems from strong ANKTIVA sales and encouraging interim results from the QUILT-2.005 study, with a potential label expansion in 2027. Additionally, positive Phase 2 QUILT-3.078 results for recurrent GBM show promising survival data.
ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock
ImmunityBio (IBRX) shares rose 6% to $6.25 as traders focus on the company's upcoming FDA resubmission for ANKTIVA, targeting label expansion for papillary bladder cancer. The company plans to submit requested additional information within 30 days of January 20th. Key financial updates include a projected 2025 net product revenue of $113 million and $242.8 million in cash reserves, alongside a convertible note amendment with Nant Capital, LLC.
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
ImmunityBio, Inc. (NASDAQ:IBRX) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $11.80. Several firms recently raised their price targets for IBRX, despite company insiders selling shares worth approximately $1.53 million over the past three months. The company's shares opened at $6.25 and recorded a slight beat on EPS and revenue estimates in its latest quarter.
MAHA Action Media Hub
The MAHA Action Media Hub section of ImmunityBio's website highlights news coverage, specifically mentioning an article from January 30, 2026. The site also provides solutions for patients, opportunities for trial investigators focusing on next-generation adenovirus-vectored anti-cancer vaccines, and tools for research scientists using the NK-92® natural killer cell line for functional killing assays. ImmunityBio focuses on developing immunotherapies to enhance the patient's immune system against diseases.
ImmunityBio Stock Skyrockets Amid FDA Progress and Clinical Advances
ImmunityBio Inc. (IBRX) stock has surged by 7.28% due to promising clinical advancements and investor confidence. The company reported positive results from its CD19 CAR-NK cell therapy trials for Waldenstrom lymphoma and is in discussions with the FDA for ANKTIVA resubmission for bladder cancer. These developments, along with projections of $180M in sales for 2026, have led to bullish analyst ratings and a significant increase in its stock price.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX
Pomerantz LLP is investigating potential securities fraud claims against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of its investors. This investigation follows a 12.13% stock price drop after the company announced updated Phase 2 clinical results for its glioblastoma treatment, noting that the primary endpoint of "median overall survival" had not yet been reached. Investors affected by the stock decline are encouraged to contact the law firm.
ImmunityBio Stocks Surge Amid Clinical Advances and Strategic Growth
ImmunityBio Inc. (NASDAQ: IBRX) stock has seen a 3.19% surge due to promising clinical advances, including accelerated FDA approval in Saudi Arabia for its therapeutic ANKTIVA for cancer treatment, and ongoing discussions with the U.S. FDA for bladder cancer. The company reported a 700% yearly revenue increase and strong product unit growth, demonstrating significant financial and strategic progress. These developments highlight ImmunityBio's proactive approach to market expansion and addressing unmet medical needs in oncology.
ImmunityBio (IBRX) Sheds 4% on Profit-Taking After 14-Day Run
ImmunityBio Inc. (IBRX) saw a 4.19% decline after 14 consecutive days of gains, as investors engaged in profit-taking. Despite the recent dip, the company's stock had surged 271% for the month of January due to positive clinical trial results, a significant sales increase for its Anktiva therapy, and international market expansion. ImmunityBio is also expected to release detailed results from its QUILT-3.078 Phase 2 study for glioblastoma treatment.
ImmunityBio (IBRX) Sheds 4% on Profit-Taking After 14-Day Run
ImmunityBio (IBRX) saw its stock price drop by 4.19% on Tuesday, closing at $5.95 per share, as investors took profits following 14 consecutive days of gains. Despite this recent decline, the company's stock had soared by 271% in January up to January 22nd, driven by positive clinical trial results, a 700% sales increase for its Anktiva therapy, and international expansion. ImmunityBio is also expected to release detailed results from its QUILT-3.078 Phase 2 study for glioblastoma treatment, which has shown a manageable safety profile in enrolled patients.
ImmunityBio (IBRX) Sheds 4% on Profit-Taking After 14-Day Run
ImmunityBio (IBRX) experienced a 4% decline due to profit-taking after 14 consecutive days of gains, closing at $5.95. Despite this recent drop, the company had seen a 271% increase in January, driven by positive clinical trial results, a significant sales jump for its Anktiva therapy, and international expansion. ImmunityBio is also expected to release detailed results from its QUILT-3.078 Phase 2 study for glioblastoma treatment.
ImmunityBio Glioblastoma Data Add Fuel To Rapidly Moving IBRX Story
ImmunityBio reported updated Phase 2 data from its QUILT-3.078 trial for recurrent glioblastoma, showing promising median overall survival with most patients alive and maintaining immune function. This news further boosts IBRX stock, which has seen significant gains year-to-date, and reinforces the company's strategy of using its ANKTIVA and CAR-NK platforms across various hard-to-manage cancers. Investors should monitor future trial enrollments, regulatory interactions, and financing activities due to the stock's volatility and the company's cash runway.
ImmunityBio Glioblastoma Data Add Fuel To Rapidly Moving IBRX Story
ImmunityBio (IBRX) released updated Phase 2 data for its ANKTIVA plus CAR-NK therapy in recurrent glioblastoma, showing promising median overall survival not yet reached and a manageable safety profile without chemotherapy. This positive news comes as ImmunityBio's stock has seen significant gains, with returns of 190.2% over the past 30 days. The data reinforces the company's strategy of using a common immunotherapy backbone for various cancers and could expand ANKTIVA's addressable market.
FDA Inquiry Pushes ImmunityBio Shares Down in Pre-Market
ImmunityBio Inc. (IBRX) shares dropped over 3.7% in pre-market trading after the FDA requested additional information regarding its cancer treatment application, specifically for Anktiva combined with Bacillus Calmette-Guerin. This regulatory hurdle, concerning a non-muscle invasive bladder cancer treatment, has raised investor concerns and highlights the company's financial strain, as reflected in its significant operational losses despite high gross margins. The company faces a challenging path forward until it can address the FDA's queries and align its financial performance with market expectations.
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer
ImmunityBio (IBRX) shares surged again after the FDA outlined a potential resubmission path for its ANKTIVA therapy in BCG-unresponsive papillary bladder cancer. This positive update follows a week of significant gains for the company, driven by the expanding potential indications and geographic markets for ANKTIVA. Despite the stock's volatility, investors are reacting positively to the news, which suggests a promising future for the therapy.
ImmunityBio (IBRX) stock slips after SEC filing tweaks $505 million insider note — what traders watch next
ImmunityBio (IBRX) shares declined after an SEC filing revealed amended terms for a $505 million convertible note, allowing partial conversions into stock, which traders view as a dilution risk. The company is facing upcoming catalysts, including a glioblastoma data presentation on January 31 and a 30-day window for an FDA resubmission package following a recent regulatory update on ANKTIVA. Analysts maintain a "buy" rating with an increased price target, but the note amendment introduces a new factor for potential stock volatility.
IBRX Stock Gains Pre-Market After A Volatile Trading Session Following Phase 2 Glioblastoma Trial Update: Retail Backs ImmunityBio’s Cancer Research
ImmunityBio (IBRX) shares saw pre-market gains after founder Patrick Soon Shiong clarified the positive implications of its Phase 2 glioblastoma trial. Despite not yet reaching median survival for Anktiva + CAR-NK patients, the fact that patients are alive at 12 months and median survival hasn't been reached is considered promising. Retail investors on Stocktwits reacted with extreme bullishness, expressing strong confidence in the company's future and its potential to revolutionize cancer treatment.
HC Wainwright Issues Positive Forecast for ImmunityBio (NASDAQ:IBRX) Stock Price
HC Wainwright has increased its price target for ImmunityBio (NASDAQ:IBRX) from $8.00 to $10.00, reiterating a "buy" rating and suggesting a potential upside of over 55%. This positive outlook comes despite recent insider selling, with directors Christobel Selecky and Barry J. Simon collectively selling shares worth approximately $1.28 million, although insiders still own a significant 69.48% of the company. The biotech firm also reported an EPS of ($0.07) for its last quarter, beating consensus estimates, and analysts anticipate an average target price of $11.80 for the stock.
ImmunityBio amends $505 million convertible note to allow partial conversions
ImmunityBio, Inc. (NASDAQ:IBRX) has amended a $505 million convertible promissory note with Nant Capital, LLC, an entity affiliated with its Executive Chairman, Dr. Patrick Soon-Shiong. The key change allows the noteholder to convert any portion of the outstanding principal into company common stock at any time before maturity, which was previously not permitted. This amendment, announced Monday, follows other positive developments for ImmunityBio, including constructive FDA discussions for ANKTIVA, progress in its QUILT-2.005 trial, and positive analyst price target raises.
